title: Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy.
abstract: OBJECTIVE
  We analyzed survival, therapeutic response, and prognostic factors in patients with HIV-related Hodgkin lymphoma (HL) treated or not with highly active antiretroviral therapy (HAART).
  
  
  METHODS
  This study included 104 patients with HL, treated (n = 83) or not (n = 21) with HAART. Outcomes and prognostic factors of complete remission (CR), overall survival (OS), and disease-free survival (DFS) were assessed by an intention-to-treat analysis of all patients who received at least 1 chemotherapy course.
  
  
  RESULTS
  No differences were found between groups at baseline in the specific characteristics of HIV and HL. The proportion of patients receiving appropriate-for-stage therapy for HL was similar for both groups. The CR rates in the HAART (-) and HAART (+) groups were 14 (70%) of 20 versus 71 (91%) of 78 (P = 0.023). The median OS in the HAART (-) group was 39 months (95% confidence interval [CI]: 0 to 89) and was not reached in the HAART (+) group (P = 0.0089). The median DFS in the HAART (-) group was 85 months (95% CI: 73 to 97) and was not reached in the HAART (+) group (P = 0.129). Factors independently associated with CR by logistic regression analysis were appropriate-for-stage therapy of HL, HAART, and baseline CD4 count > or =100 cells/microL. CR was the only factor independently associated with OS by Cox regression analysis.
  
  
  CONCLUSIONS
  The achievement of CR was independently associated with appropriate-for-stage therapy for HL, with HAART, and with a baseline CD4 count > or =100 cells/microL. The only variable independently associated with OS was the achievement of CR.
authors.affiliation: Hospital Gregorio Marañón, Madrid, Spain. juaberber@terra.es
authors.forename: Juan
authors.initials: J
authors.lastname: Berenguer
authors.forename: Pilar
authors.initials: P
authors.lastname: Miralles
authors.forename: José María
authors.initials: JM
authors.lastname: Ribera
authors.forename: Rafael
authors.initials: R
authors.lastname: Rubio
authors.forename: Eulalia
authors.initials: E
authors.lastname: Valencia
authors.forename: Beatriz
authors.initials: B
authors.lastname: Mahillo
authors.forename: Vicente
authors.initials: V
authors.lastname: Pintado
authors.forename: Rosario
authors.initials: R
authors.lastname: Palacios
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Montes
authors.forename: María Jesús
authors.initials: MJ
authors.lastname: Téllez
authors.forename: José
authors.initials: J
authors.lastname: La Cruz
authors.forename: Julián
authors.initials: J
authors.lastname: Torre-Cisneros
authors.forename: Francisco
authors.initials: F
authors.lastname: Rodríguez-Arrondo
authors.forename: María Antonia
authors.initials: MA
authors.lastname: Sepúlveda
authors.forename: Félix
authors.initials: F
authors.lastname: Gutiérrez
authors.forename: Galo
authors.initials: G
authors.lastname: Peralta
authors.forename: Vicente
authors.initials: V
authors.lastname: Boix
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D012042:Registries / Q000706:statistics & numerical data; D012074:Remission Induction; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome